News und Analysen

NIKE, Inc. (NYSE: NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.40 per share on the Company’s outstanding Class A and Class B Common Stock payable on

NIKE, Inc. (NYSE: NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.40 per share on the Company’s outstanding Class A and Class B Common Stock payable on

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.

Fourth Quarter 2024 Financial Highlights:

• 
  Revenue grew 8%

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.

Fourth Quarter 2024 Financial Highlights:

• 
  Revenue grew 8%

D.R. Horton, Inc. (NYSE:DHI), America’s Builder, announced that the Company will present to the investment community via webcast at the 2025 Barclays 42^nd Annual Industrial Select Conference on

D.R. Horton, Inc. (NYSE:DHI), America’s Builder, announced today that the Company will release financial results for its second quarter ended March 31, 2025 on Thursday, April 17, 2025 before the

VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that after 13 years with the Company, George E. Kilguss III

VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that after 13 years with the Company, George E. Kilguss III

VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that after 13 years with the Company, George E. Kilguss III

Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA^® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA^® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI

Walmart Inc. (NYSE: WMT) announced it will hold a live conference call with the investment community at 7 a.m. CST on Thursday, Feb. 20, 2025, to discuss the company's fourth quarter and full-year

Walmart Inc. (NYSE: WMT) announced it will hold a live conference call with the investment community at 7 a.m. CST on Thursday, Feb. 20, 2025, to discuss the company's fourth quarter and full-year

CRH (NYSE: CRH), the leading provider of building materials solutions, will publish its fourth quarter and full year 2024 financial results after the U.S. market closes on Wednesday, February 26

Howmet Aerospace (NYSE:HWM):

Fourth Quarter 2024 GAAP Financial Results

• 
  Revenue of $1.9 billion, up 9% year over year, driven by Commercial Aerospace, up 13%
  


• 
  Net Income of $314 million

Intelligent power management company Eaton (NYSE:ETN) today announced it will host its 2025 investor conference on Tuesday, March 11, 2025, from 2 p.m. to 5:30 p.m. Eastern time. The purpose of the

Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

Copart, Inc. (NASDAQ: CPRT) announced today that it will release earnings for the second quarter of fiscal 2025 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 20, 2025.

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the full year and fourth quarter ended December 31, 2024.

CEO Remarks

“Ventas delivered strong financial

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS^® (brentuximab vedotin) in

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS^® (brentuximab vedotin) in